FDA Approves Nivolumab for MSI-H or dMMR Colorectal Cancer
Tuesday, Aug 01, 2017
The FDA has granted an accelerated approval to nivolumab (Opdivo) for the treatment of adult and pediatric patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
“Patients with metastatic colorectal cancer who have dMMR or MSI-H tumors are less likely to respond to conventional chemotherapy,” Heinz-Josef Lenz, MD, J. Terrence Lanni Chair in Gastrointestinal Cancer Research, University of Southern California, said in a statement. “While the challenges of treating these patients have been significant, tumors characterized by these biomarkers are immunogenic. Therefore, advances in immunotherapy research are encouraging in presenting new treatment options for appropriate patients with MSI-H metastatic colorectal cancer.”
http://www.onclive.com/web-exclusives/f ... tal-cancer